Plinest (1 x 2ml Syringe, 20 mg/ml Polynucleotides PN HPT)

Plinest

Injectable skin booster

Polynucleotide (PN-HPT\u00ae) bio-revitalising gel for intradermal use

Class III CE Marked medical device based on PN HPT® polynucleotides for intradermal injection.
Manufactured by Mastelli S.r.l. Officina Bio Farmaceutica in EU facilities operating under recognised quality management and Good Manufacturing Practice standards.
Included in published clinical literature as a CE Marked PN HPT® 20 mg/ml polynucleotide gel in 2 ml pre Filled sterile syringes for skin rejuvenation.
Distributed in the UK via licensed aesthetic pharmacies such as The Crystal Pharmacy, which operate under General Pharmaceutical Council (GPhC) oversight for medicines and aesthetic products supply.

Class III CE Marked medical device based on PN HPT® polynucleotides for intradermal injection.
Manufactured by Mastelli S.r.l. Officina Bio Farmaceutica in EU facilities operating under recognised quality management and Good Manufacturing Practice standards.
Included in published clinical literature as a CE Marked PN HPT® 20 mg/ml polynucleotide gel in 2 ml pre Filled sterile syringes for skin rejuvenation.
Distributed in the UK via licensed aesthetic pharmacies such as The Crystal Pharmacy, which operate under General Pharmaceutical Council (GPhC) oversight for medicines and aesthetic products supply.

Polynucleotide (PN-HPT\u00ae) bio-revitalising gel for intradermal use

Description

Plinest (1 x 2ml Syringe) is an injectable polynucleotide (PN-HPT®) skin booster designed for intradermal use on the face, neck and décolletage. It contains highly purified long-chain polynucleotides at a concentration of 20 mg/ml in a 2 ml pre-filled syringe. These DNA fragments, obtained using PN-HPT® (Polynucleotides Highly Purified Technology), stimulate fibroblast activity, supporting the production of collagen and elastin, improving skin hydration and elasticity, and promoting tissue repair. The treatment aims to deliver firmer, smoother, more radiant skin with minimal invasiveness and natural-looking results, and is indicated for prevention and early treatment of visible signs of ageing as well as for general improvement of skin quality.

Bnefits

Stimulates collagen and elastin production, helping to firm and smooth the skin
Boosts skin moisture levels, reducing the appearance of fine lines and wrinkles
Improves overall skin quality, tone and texture for a more radiant complexion
Supports tissue repair and bio-regeneration in photoaged or stressed skin
Enhances skin elasticity and resilience by activating fibroblast activity
Designed to be minimally invasive while providing natural-looking results
Can be used to maintain and improve skin quality in younger patients as a preventative treatment
Suitable for key aesthetic areas such as the face, neck and décolletage

Indications

Improvement of skin quality, tone and texture in the face, neck and décolletage
Fine lines and superficial wrinkles associated with early skin ageing
Mild to moderate loss of firmness and elasticity
Dull, dehydrated or photoaged skin requiring increased hydration and radiance
Preventative and maintenance treatment of skin quality in younger patients
Adjunctive use in broader aesthetic treatment plans where skin priming and bio-revitalisation are desired

Composition

Polynucleotides (PN-HPT® – highly purified long-chain DNA polymers) 20 mg/ml in a 2 ml gel
Sterile, non-pyrogenic viscoelastic gel vehicle suitable for intradermal injection
Polynucleotides derived from fish (trout) DNA, purified to remove proteins and other impurities to maximise biocompatibility

Formulation

Concentration: 20 mg/ml polynucleotides (PN-HPT®)
Volume: 2 ml pre-filled sterile syringe for intradermal injection
Class III CE-marked medical device formulated as a viscoelastic gel for skin bio-revitalisation

Packaging

1 x 2 ml pre-filled Plinest syringe per box
2 x 30G ½" (13 mm) sterile needles supplied in the pack
Sterile blister packaging for syringe and needles
Labelled as a Class III CE medical device for intradermal use

Usage

For professional use only; must be administered by an appropriately trained healthcare professional in accordance with local regulations and the official Instructions for Use (IFU).
Intended route: intradermal injection using micro-depot, micro-papular or linear retrograde techniques, following manufacturer and consensus PN-HPT® protocols.
Typical protocols described for Plinest/PN-HPT® 20 mg/ml include a course of 3–4 treatment sessions spaced approximately 14–21 days apart, with maintenance sessions thereafter according to clinical judgement.
Treatment areas commonly include face, neck and décolletage; injection patterns and depth should respect anatomical safety zones.
Do not mix Plinest with other products in the same syringe; apply on cleansed, disinfected skin using strict aseptic technique.
Single-use medical device: use immediately after opening; discard any unused product and all sharps according to local clinical waste regulations.
Practitioners should refer to Mastelli’s official Plinest documentation and evidence-based PN-HPT® treatment guidelines for detailed dosing, injection patterns and patient selection.

Contraindications

Use is contraindicated in patients with known hypersensitivity or allergy to fish-derived products, polynucleotides or any component of the formulation.
Do not inject into areas with active skin infections, inflammatory dermatoses, or compromised skin integrity at the intended treatment site.
General contraindications to injectable aesthetic procedures apply, including uncontrolled systemic disease, active autoimmune disease involving the skin, and significant bleeding or coagulation disorders, unless the prescriber determines otherwise.
Use is generally avoided during pregnancy and breastfeeding, in line with standard practice for aesthetic injectable treatments, unless explicitly permitted by product labelling and local regulations.
Practitioners must consult the official Mastelli Plinest Instructions for Use (IFU) for the complete and authoritative list of contraindications and precautions before treating patients.

Adverse Effects

As with other intradermal injectable treatments, common transient reactions may include redness (erythema), mild swelling or oedema, tenderness, itching, small papules at injection points and minor bruising at the treatment site; these typically resolve spontaneously within a few days.
Less common adverse effects may include local inflammatory reactions or prolonged swelling; patients should be advised to contact their practitioner if symptoms persist or worsen.
Although polynucleotides purified with PN-HPT® technology are designed for high biocompatibility, hypersensitivity or allergic reactions are theoretically possible and should be managed according to standard medical practice.
Serious complications such as infection, abscess formation or vascular events are rare but possible with any injectable procedure; strict aseptic technique, appropriate injection technique and adherence to anatomical safety guidelines are essential.
All suspected serious adverse events should be reported through the appropriate medical device vigilance and pharmacovigilance channels according to local regulations.

Storage Conditions

Store between 2°C and 25°C, in accordance with typical PN-HPT®/Plinest distributor guidance.
Do not freeze; avoid exposure to excessive heat, direct sunlight or high humidity.
Keep the syringe in its original packaging until use to maintain sterility and protect from light and contamination.
Do not use the product if the packaging is damaged, the sterility seal is broken, or the expiry date has passed.
Keep out of the reach of children.
Single-use device: after opening and use, dispose of any remaining product and all sharps and packaging as clinical waste in line with local regulations.

Duration

An initial treatment course typically consists of 3\u20134 intradermal sessions using 1 x 2 ml syringe per session, spaced about every 2\u20133 weeks (14\u201321 days). Clinical and manufacturer-supported protocols then recommend maintenance sessions every 2\u20133 months (or tailored to the individual) to sustain results. Improvements in skin quality can persist for several months following a completed course when appropriate maintenance is carried out.

Onset

Instrumental and clinical data on PN-HPT\u00ae devices such as Plinest indicate progressive improvement over several weeks. Patients often begin to notice enhanced hydration and texture within a few weeks of starting treatment, with more visible improvements in fine lines, firmness and overall skin quality typically evident around 4\u20138 weeks after an initial series of sessions, and continuing to stabilise with ongoing maintenance.